MTOR and renal cell carcinoma: The next step is to explore how DEPDC1 regulates the AKT/mTOR/HIF1α pathway and key glycolytic enzymes, and to verify the effects of DEPDC1 in primary drug-resistant tumor animal models of renal cell carcinoma.